The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | The recent withdrawal of voxelotor from the market: the potential impact on patients with SCD
Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Trust, London, UK, discusses the recent withdrawal of voxelotor from the market, commenting on the impact this may have on the treatment landscape for adult patients with sickle cell disease (SCD). Dr Chakravorty hopes that the recent withdrawal of two agents from the market will not reduce investment in drug development for SCD. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria for participation in this meeting provided by Vertex Pharmaceuticals; Research funding: Pfizer, Global Blood Therapeutics, Forma therapeutics, Nova laboratories; Honoraria for EHA 2024 Congress: Vertex Pharmaceuticals, Sobi.
